Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03888105 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
A Phase 2 study of B-cell Non-Hodgkin Lymphoma (B-NHL), sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 515
- Enrollment target
- 20
- Study locations
NCT03888105 is a Phase 2 study of B-cell Non-Hodgkin Lymphoma (B-NHL) that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 515 participants, above the 70-participant average among 3 other B-cell Non-Hodgkin Lymphoma (B-NHL) trials with a reported enrollment target (636% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT03888105, a Phase 2 study of B-cell Non-Hodgkin Lymphoma (B-NHL), is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 515 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab. The study is looking at several other research questions, including: * To see if odronextamab works to destroy cancer cells * Side effects that may be experienced by people taking odronextamab * How odronextamab works in the body * How much odronextamab is present in the blood
Conditions Studied
Interventions
- DRUG Odronextamab
Study Locations (20)
Victoria
- Epworth Hospital - East Melbourne
- North Building - Frankston
- Andrew Love Cancer Centre - Geelong
- Olivia Newton John Cancer Wellness & Research Centre - Heidelberg
Massachusetts
- Tufts Medical Center - Boston
- Beth Israel Deaconess Medical Center - Boston
New York
- Weill Cornell Medical College New York Presbyterian Hospital - New York
- Stony Brook University Hospital - Stony Brook
Illinois
- Rush University Medical Center - Chicago
Iowa
- University of Iowa - Iowa City
Kentucky
- Norton Cancer Institute - Louisville
Minnesota
- Mayo Clinic - Rochester - Rochester
New Jersey
- John Theurer Cancer Center at Hackensack UMC - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 515 participants |
| Start Date | 2019-11-13 |
| Est. Completion | 2028-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03888105
The ClinicalTrials.gov registry entry for NCT03888105 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 515 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 70-participant average among 3 other B-cell Non-Hodgkin Lymphoma (B-NHL) trials with a reported enrollment target (636% higher). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with B-cell Non-Hodgkin Lymphoma (B-NHL) appearing as the primary indexed condition, and to 1 intervention - of which Odronextamab is the first listed.
NCT03888105 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Victoria, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT03888105 about?
NCT03888105 is a clinical study titled "A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies". This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab. The study is lookin...
What is the current status of trial NCT03888105?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 515 participants. The study started on 2019-11-13. Estimated completion is 2028-12-15.
What conditions does trial NCT03888105 study?
This clinical trial studies the following conditions: B-cell Non-Hodgkin Lymphoma (B-NHL).
What interventions are being tested in trial NCT03888105?
The interventions under investigation include: Odronextamab (DRUG).
Who is sponsoring clinical trial NCT03888105?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03888105 being conducted?
This trial has 20 study locations across Illinois, Iowa, Kentucky, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for B-cell Non-Hodgkin Lymphoma (B-NHL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.